Travere Therapeutics Inc (TVTX)

16.42 +0.11 (+0.67%)
Closed USD Disclaimer
16.42 -0.00 (-0.00%)

Travere Therapeutics Inc Company Profile

Equity Type
Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's lead clinical program includes FILSPARI to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression and Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
Contact Information
San Diego,92130 United States
888 969 7879
Top Executives
Eric M. Dube 48 2019 President, CEO & Director
Timothy P. Coughlin 54 2015 Independent Director
Gary A. Lyons 70 2014 Independent Chairman of the Board
Jeffrey A. Meckler 54 2014 Independent Director
John A. Orwin 56 2017 Independent Director
Alan H. Beggs 0 0000 Member of Scientific Advisory Board
Stuart J. Swiedler 65 0000 Member of Scientific Advisory Board
Sandra E. Poole 58 2019 Independent Director
Roy D. Baynes 67 2016 Independent Director
Ruth Evelyn Williams-Brinkley 69 2021 Independent Director
Ron Squarer 55 2017 Independent Director
Suzanne L. Bruhn 59 2020 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.